###begin article-title 0
###xml 100 101 100 101 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fn" rid="fn1">*</xref>
###xml 101 103 101 103 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fn" rid="fn2">s&#8414;</xref>
Association of the novel cardiovascular risk factors paraoxonase 1 and cystatin C in type 2 diabetes*sâƒž
###end article-title 0
###begin p 1
###xml 52 79 52 79 <email xmlns:xlink="http://www.w3.org/1999/xlink">connellyp@smh.toronto.on.ca</email>
To whom correspondence should be addressed. e-mail: connellyp@smh.toronto.on.ca
###end p 1
###begin p 2
###xml 0 15 0 15 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Author's Choice</bold>
###xml 0 44 0 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink"><bold>Author's Choice</bold> - Final version full access.</italic>
Author's Choice - Final version full access.
###end p 2
###begin p 3
 applies to Author Choice Articles
###end p 3
###begin p 4
###xml 405 409 405 409 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PON1</italic>
###xml 423 427 423 427 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PON2</italic>
###xml 616 617 616 617 <sub xmlns:xlink="http://www.w3.org/1999/xlink">e</sub>
###xml 692 696 692 696 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PON2</italic>
###xml 872 876 872 876 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PON2</italic>
###xml 1022 1023 1022 1023 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 1148 1149 1148 1149 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 1269 1270 1269 1270 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
Paraoxonase 1 (PON1) has been reported to be associated with proteinuria in subjects with type 2 diabetes mellitus (T2DM). Plasma cystatin C is more accurate than creatinine for identifying stage 3 kidney disease in T2DM. We tested the hypothesis that PON1 and cystatin C would be associated in T2DM subjects from an Aboriginal Canadian community, who are at high risk for the development of nephropathy. PON1 A(-162)G and PON2 Ala148Gly genotypes, cystatin C, HbA1c, high density lipoprotein cholesterol (HDLC), waist circumference (waist), and duration of diabetes were included in the regression analysis with loge (ln) of PON1 mass as the dependent variable. A regression model including PON2 Ala148Gly genotype, HDLC, and ln cystatin C explained 25.8% of the variance in PON1 mass. Conversely, waist, age, ln HbA1c, ln duration of diabetes, and ln PON1 mass, but not PON2 genotype, explained 38% of the variance in cystatin C. Subjects with cystatin C estimated glomerular filtration rate (eGFR) <60 ml/min per 1.73 m2 (stage 3 kidney disease) had significantly lower PON1 mass compared with subjects with cystatin C-eGFR >60 ml/min per 1.73 m2. The lower mass of PON1, an anti-inflammatory HDL-associated enzyme, in T2DM with cystatin C-eGFR <60 ml/min per 1.73 m2 may contribute to their increased risk for cardiovascular disease.
###end p 4
###begin p 5
Published, JLR Papers in Press, January 18, 2009.
###end p 5
###begin p 6
###xml 143 144 143 144 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib1">1</xref>
###xml 144 144 144 144 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib2"/>
###xml 144 144 144 144 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib3"/>
###xml 145 146 145 146 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib4">4</xref>
###xml 222 223 222 223 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib5">5</xref>
###xml 293 294 293 294 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib6">6</xref>
###xml 393 394 393 394 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib7">7</xref>
###xml 514 515 514 515 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib8">8</xref>
###xml 608 609 608 609 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib9">9</xref>
###xml 651 655 651 655 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PON1</italic>
###xml 928 930 928 930 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib10">10</xref>
###xml 947 948 947 948 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib9">9</xref>
###xml 1007 1011 1007 1011 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PON1</italic>
###xml 1200 1204 1200 1204 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PON1</italic>
###xml 1266 1268 1266 1268 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib11">11</xref>
###xml 1283 1285 1283 1285 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib10">10</xref>
###xml 1287 1289 1287 1289 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib12">12</xref>
###xml 245 249 <span type="species:ncbi:10090">mice</span>
###xml 300 305 <span type="species:ncbi:9606">human</span>
Paraoxonase 1 (PON1) (arylesterase; EC 3.1.1.2) is an HDL-associated enzyme that hydrolyzes organophosphate compounds and fatty acid lactones (1-4). PON1 activity has been inversely associated with cardiovascular disease (5), and PON1-deficient mice are more prone to develop atherosclerosis (6). In human studies, PON1 activity is significantly lower in subjects with the metabolic syndrome (7). PON1 activity was recently shown to be reduced in subjects with type 1 and type 2 diabetes mellitus (T1DM and T2DM) (8) and was inversely associated with glucose concentrations in subjects with type 1 diabetes (9). Subjects with the Arg192 allele of the PON1 gene had an odds ratio of 3.21 for the presence of retinopathy and/or nephropathy compared with subjects who were homozygous for the Gln192 allele in a Japanese cohort. The Japanese are known to have a higher frequency of the minor Arg192 allele compared with Caucasians (10). Hofer et al. (9) reported that homozygosity for the minor A allele of the PON1 A(-162)G promoter polymorphism was associated with microalbuminuria in an adolescent Australian cohort of subjects with T1DM. Furthermore, several studies have reported the association of PON1 gene variants with increased diabetic complications in T1DM (11) and in T2DM (10, 12).
###end p 6
###begin p 7
###xml 26 30 26 30 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PON2</italic>
###xml 119 121 119 121 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib13">13</xref>
###xml 123 125 123 125 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib14">14</xref>
###xml 326 330 326 330 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PON2</italic>
###xml 420 422 420 422 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib15">15</xref>
###xml 467 471 467 471 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PON2</italic>
We have reported that the PON2 polymorphism Ala148Gly is associated with diabetes in a cohort of Aboriginal Canadians (13, 14). In a prospective study of 3,374 predominantly Caucasian subjects (the United Kingdom Prospective Diabetes Study), with a median duration of diabetes of 14 years, it was found that heterozygotes for PON2 Ala148Gly polymorphism had a 1.25 relative risk for the development of microalbuminuria (15). However, there are no previous studies of PON2 polymorphisms and PON1 mass.
###end p 7
###begin p 8
###xml 128 130 128 130 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib16">16</xref>
###xml 132 134 132 134 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib17">17</xref>
###xml 265 267 265 267 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib18">18</xref>
###xml 442 444 442 444 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib19">19</xref>
###xml 446 448 446 448 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib20">20</xref>
###xml 601 603 601 603 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib19">19</xref>
###xml 603 603 603 603 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib20"/>
###xml 604 606 604 606 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib21">21</xref>
Relatively little information is available regarding circulating PON1 mass in subjects with and without diabetic complications (16, 17). This issue is of interest due to the hypothesized role of oxidative stress in the development of the complications of diabetes (18). Furthermore, we are unaware of any studies of PON1 mass and diabetic complications among Aboriginal populations, who are at high risk for diabetes and associated sequelae (19, 20). In particular, it is well documented that Aboriginal Canadian subjects with diabetes have high rates of microalbuminuria and end stage renal disease (19-21), suggesting that kidney dysfunction may be the predominant microvascular complication of diabetes in this population. Our objective, therefore, was to determine the association of PON1 mass with cystatin C, a marker of renal function, in a sample of Aboriginal Canadians with T2DM.
###end p 8
###begin title 9
RESEARCH DESIGN AND METHODS
###end title 9
###begin p 10
###xml 116 118 116 118 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib21">21</xref>
###xml 328 330 328 330 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib21">21</xref>
###xml 332 334 332 334 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib22">22</xref>
###xml 614 626 <span type="species:ncbi:9606">participants</span>
The methodology of the Sandy Lake Diabetes Complications Study (2001-2002) has been presented in detail previously (21). Briefly, the research project was conducted in partnership with a Canadian Aboriginal community currently experiencing high rates of T2DM, with an early age of disease onset and high rates of complications (21, 22). All community members known to have T2DM were invited to participate; 189 of 250 (76%) eligible subjects were enrolled. Serum samples were available for the measurement of PON1 mass for 106 of these subjects (44 males/62 females). Signed informed consent was obtained from all participants, and the study was approved by the Sandy Lake First Nation Band Council and the Mount Sinai Hospital Ethics Review Committee.
###end p 10
###begin p 11
###xml 76 78 76 78 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib21">21</xref>
###xml 200 202 200 202 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib23">23</xref>
###xml 279 280 279 280 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r</italic>
###xml 320 322 320 322 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib24">24</xref>
Validated measures were used to assess nephropathy as described previously (21). Diabetic nephropathy was determined by measuring the albumin:creatinine ratio in a single random daytime urine sample (23) using the Bayer DCA 2000 Point-of-Care Analyzer, which had been validated (r = 0.95) against laboratory techniques (24).
###end p 11
###begin p 12
###xml 50 51 50 51 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r</italic>
###xml 90 92 90 92 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib25">25</xref>
###xml 283 285 283 285 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib26">26</xref>
###xml 481 483 481 483 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib21">21</xref>
###xml 532 534 532 534 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib27">27</xref>
###xml 773 778 773 778 <sup xmlns:xlink="http://www.w3.org/1999/xlink">1.333</sup>
###xml 781 783 781 783 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib28">28</xref>
HbA1c was determined using the DCA 2000 analyzer (r = 0.90-0.98 vs. laboratory measures) (25). Lipid, lipoprotein, and creatinine concentrations were determined using standard laboratory methods. The Cockcroft-Gault equation was used for estimated glomerular filtration rate (eGFR) (26). Height, weight, and waist circumference, systolic and diastolic blood pressure, duration of diabetes, and method of diabetes and hypertension treatment were determined as previously described (21). Cystatin C, a novel surrogate measure of GFR (27), was determined using the Behring N latex Cystatin C reagent and the Behring BN100 instrument according to manufacturer's protocols. The cystatin C-estimated GFR was calculated using the Arnal equation as follows: Cys-eGFR = 74.835/(CysC1.333) (28).
###end p 12
###begin p 13
###xml 228 230 228 230 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib29">29</xref>
###xml 78 83 <span type="species:ncbi:9606">human</span>
###xml 163 168 <span type="species:ncbi:10090">mouse</span>
###xml 430 435 <span type="species:ncbi:9606">human</span>
PON1 mass was determined using SDS-electrophoresis and Western blot with anti-human PON1 monoclonal antibody 4C10 as the primary antibody and Alexa Fluor 680 anti-mouse IgG (catalog number A21065; Alexa) as the second antibody (29) (see supplementary Fig. I). Detection and quantitation was done with the Licor Odyssey (Omaha, NE). Between-day coefficient of variation was 7.8%. A reference serum was calibrated using recombinant human paraoxonase-1 (Cedarlane Laboratories, Ontario, Canada).
###end p 13
###begin p 14
###xml 13 17 13 17 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PON1</italic>
###xml 71 75 71 75 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PON2</italic>
###xml 142 143 142 143 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib9">9</xref>
###xml 145 147 145 147 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib30">30</xref>
###xml 149 151 149 151 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib31">31</xref>
Genotypes of PON1 Gln192 Arg, Met55Leu, and A(-162)G polymorphisms and PON2 Ala148Gly polymorphism were determined using established methods (9, 30, 31).
###end p 14
###begin title 15
Statistical methods
###end title 15
###begin p 16
###xml 224 228 224 228 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PON1</italic>
###xml 242 246 242 246 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PON2</italic>
###xml 364 365 364 365 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 718 720 718 720 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib21">21</xref>
Analyses were conducted using PON1 mass as well as the ratios of PON1/HDLC and PON1/apo AI, which were calculated to account for the demonstrated stabilizing effect of HDL and apolipoprotein AI (apoAI) on PON1. Genotypes of PON1 A(-162)G and PON2 Ala148Gly were entered into models as discrete independent variables. Differences between means were evaluated using t-tests, and univariate associations between continuous variables were assessed using Spearman correlation analysis. Independent associations of PON1 with the continuous outcomes cystatin C and eGFR were determined using multiple linear regression, with covariates included based on previous analysis of diabetic kidney complications in this population (21). All analyses were conducted using SAS version 9.1 (SAS Institute, Carey, NC).
###end p 16
###begin title 17
RESULTS
###end title 17
###begin p 18
###xml 159 166 159 166 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Table 1</bold>
###xml 159 166 159 166 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="tbl1"><bold>Table 1</bold></xref>
###xml 285 286 285 286 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r</italic>
###xml 298 299 298 299 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r</italic>
###xml 327 328 327 328 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 434 435 434 435 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r</italic>
###xml 445 446 445 446 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 455 456 455 456 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r</italic>
###xml 469 470 469 470 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r</italic>
###xml 485 486 485 486 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 510 517 510 517 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Table 2</bold>
###xml 510 517 510 517 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="tbl2"><bold>Table 2</bold></xref>
###xml 15 27 <span type="species:ncbi:9606">participants</span>
Although study participants were relatively young (mean age of 46 years), the average duration of diabetes was 8.4 years and metabolic control was suboptimal (Table 1). In univariate correlation analysis, PON1/HDLC and PON1/apoAI were significantly positively correlated with eGFR-CG (r = 0.37 and r = 0.28, respectively, both P < 0.001), while PON1, PON1/HDLC, and PON1/apoAI showed significant inverse correlations with cystatin C (r = -0.22, P < 0.05; r = -0.30 and r = -0.29, both P < 0.01, respectively) (Table 2). PON1 showed no correlation with urinary albumin/creatinine ratio.
###end p 18
###begin p 19
###xml 19 31 <span type="species:ncbi:9606">participants</span>
Characteristics of participants: Sandy Lake Complications Prevalence and Risk Factor Study, 2001-2002
###end p 19
###begin p 20
BMI, body mass index; BP, blood pressure.
###end p 20
###begin p 21
Cockcroft-Gault equation.
###end p 21
###begin p 22
Modification of diet in renal disease equation.
###end p 22
###begin p 23
Univariate associations of PON1, PON1/HDL, PON1/ApoA1, and other demographic and metabolic risk factors with urine albumin/creatinine ratio, estimated glomerular filtration rate, and cystatin C
###end p 23
###begin p 24
###xml 42 43 42 43 <bold xmlns:xlink="http://www.w3.org/1999/xlink">*</bold>
###xml 43 44 43 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 53 59 53 54 <bold xmlns:xlink="http://www.w3.org/1999/xlink">&#8224;</bold>
###xml 59 60 54 55 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 69 82 64 65 <bold xmlns:xlink="http://www.w3.org/1999/xlink">&#8225;</bold>
###xml 82 83 65 66 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 93 107 76 77 <bold xmlns:xlink="http://www.w3.org/1999/xlink">&#182;</bold>
###xml 107 108 77 78 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
Univariate Spearman correlation analysis. *P < 0.05; daggerP < 0.01; double daggerP < 0.001; paragraph signP < 0.0001. BP, blood pressure.
###end p 24
###begin p 25
Cockcroft-Gault equation.
###end p 25
###begin p 26
Modification of diet in renal disease equation.
###end p 26
###begin p 27
###xml 32 36 32 36 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PON1</italic>
###xml 222 226 222 226 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PON2</italic>
###xml 284 288 284 288 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PON1</italic>
###xml 302 306 302 306 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PON2</italic>
###xml 410 411 410 411 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 493 497 493 497 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PON1</italic>
###xml 684 688 684 688 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PON1</italic>
###xml 700 704 700 704 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PON1</italic>
###xml 835 839 835 839 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PON1</italic>
###xml 853 857 853 857 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PON2</italic>
###xml 933 940 933 940 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Table 3</bold>
###xml 933 940 933 940 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="tbl3"><bold>Table 3</bold></xref>
###xml 947 951 947 951 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PON2</italic>
###xml 1038 1040 1038 1040 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib13">13</xref>
###xml 1042 1044 1042 1044 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib14">14</xref>
The minor allele frequencies of PON1 amino acid polymorphisms Gln192Arg and Leu55Met and promoter polymorphism A(-162)G were 0.22(Arg192), 0.019 (Met55), and 0.11 (A(-162)), respectively. The minor allele frequency of the PON2 amino acid polymorphism Ala148Gly was 0.31 (Ala148). The PON1 A(-162)G and PON2 Ala148Gly showed significant but modest allelic association (linkage disequilibrium constant D = 0.06, P < 0.01), so these markers was considered to be independent for further analyses. PON1 Gln192Arg and Leu55Met genotypes were not significantly associated with PON1 mass (data not shown). Because of the very low frequencies (and low absolute counts) of the minor allele for PON1 Arg192 and PON1 Leu55 polymorphisms in this sample of Aboriginal Canadians, these polymorphisms were not evaluated further. However, genotypes of PON1 A(-162)G and PON2 Ala148Gly polymorphisms were each significantly associated with PON1 mass (Table 3). The PON2 polymorphism had been previously shown to be associated with diabetes in this cohort (13, 14), and among the genetic markers evaluated, it had the strongest statistical relationship with PON1 mass.
###end p 27
###begin p 28
Univariate analysis of PON1 mass by PON2 Ala148Gly and PON1 A(-162)G genotypes
###end p 28
###begin p 29
###xml 29 30 29 30 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 41 47 41 42 <bold xmlns:xlink="http://www.w3.org/1999/xlink">&#8224;</bold>
###xml 75 76 70 71 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
*Wilcoxon nonparametric test P = 0.0002. daggerWilcoxon nonparametric test P = 0.004.
###end p 29
###begin p 30
###xml 241 242 241 242 <sub xmlns:xlink="http://www.w3.org/1999/xlink">e</sub>
###xml 688 692 688 692 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PON2</italic>
###xml 833 840 833 840 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Table 4</bold>
###xml 833 840 833 840 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="tbl4"><bold>Table 4</bold></xref>
###xml 901 902 901 902 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1147 1151 1147 1151 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PON1</italic>
###xml 1182 1186 1182 1186 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PON1</italic>
###xml 1356 1363 1356 1363 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Table 5</bold>
###xml 1356 1363 1356 1363 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="tbl5"><bold>Table 5</bold></xref>
###xml 1421 1425 1421 1425 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PON2</italic>
###xml 1507 1511 1507 1511 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PON1</italic>
###xml 1535 1536 1535 1536 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
To analyze the determinants of PON1 mass, regression analysis was performed with genotype variables coded as 0 or 1 (e.g., presence or absence of genotypes 148Ala/Ala, 148Ala/Gly, and 148Gly/Gly). Analysis was performed with age, gender, loge (ln) duration of diabetes, ln HbA1c, waist circumference, high density lipoprotein cholesterol (HDLC), and ln cystatin C. It was noted that the distribution of duration of diabetes was skewed (see supplementary Fig. II), with most subjects having had diabetes of <15 years' duration. Thus, analysis is also reported with restriction to subjects with duration of diabetes <15 years. The strongest determinant of PON1 mass was the presence of the PON2 148Ala/Ala genotype, which accounted for 12.6% of the variation in PON1 mass, followed by HDLC, ln cystatin C, and ln duration of diabetes (Table 4). The remaining variables did not reach significance at the P < 0.05 level. The order of the variables was the same when the analysis was carried out for those subjects with duration of diabetes <15 years; however, duration of diabetes was no longer significant. Similarly, when the analysis was done with PON1 A(-162)G, the presence of the PON1 -162G/G genotype was the strongest determinant of mass, accounting for 8.9% of the variation in PON1 mass, followed by HDLC, ln cystatin C, and ln duration of diabetes (Table 5). When both genotypes were included in the analysis, the PON2 148Ala/Ala genotype remained the strongest determinant of PON1 mass, whereas the PON1 -162G/G genotype had a P = 0.06.
###end p 30
###begin p 31
Regression analysis of PON1 mass including PON2 genotype
###end p 31
###begin p 32
Regression analysis of PON1 mass including PON1 A(-162)G genotype
###end p 32
###begin p 33
###xml 412 419 412 419 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Table 6</bold>
###xml 412 419 412 419 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="tbl6"><bold>Table 6</bold></xref>
###xml 904 905 904 905 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r</italic>
###xml 905 906 905 906 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 1020 1021 1020 1021 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1158 1162 1158 1162 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PON2</italic>
The cross-sectional design of this study makes it difficult to assign a cause-effect relationship between variables. Thus, the complementary question was also addressed; that is, what are the determinants of cystatin C? The determinants of cystatin C were also analyzed by regression analysis with forward selection for the full cohort and with restriction to those subjects with duration of diabetes <15 years (Table 6). Both analyses ranked age, ln HbA1c, and waist circumference as the most influential variables, accounting for 15.6, 11.2, and 5.3%, respectively, of the variation in cystatin C for the full cohort. The impact of the subjects with duration of diabetes >15 years is seen, in that, when these subjects are included in the analysis, duration enters the regression model at the fourth step, whereas when they are excluded, it is not significant. PON1 mass accounts for a similar partial r2 in both analyses (2.3 and 3.5% for the full cohort and subjects with duration <15 years, respectively) but has a P value < 0.05 only for the analysis restricted to subjects with duration of diabetes of <15 years. Notably, there was no relationship of PON2 genotype with cystatin C.
###end p 33
###begin p 34
Regression analysis with ln cystatin C as the dependent variable
###end p 34
###begin p 35
NS, not significant.
###end p 35
###begin p 36
###xml 18 20 18 20 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib28">28</xref>
###xml 188 189 188 189 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 230 231 230 231 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 337 338 337 338 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 381 383 381 383 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib32">32</xref>
###xml 386 393 386 393 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Table 7</bold>
###xml 386 393 386 393 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="tbl7"><bold>Table 7</bold></xref>
Beauvieux et al. (28) reported that the Arnal-Dade formula for cystatin C-estimated GFR (cysC-eGFR) resulted in the correct estimation of GFR in both the high (GFR 67-164 ml/min per 1.73 m2) and medium (GFR 34-67 ml/min per 1.73 m2) range. Thus, the data were analyzed with subjects classified as cysC-eGFR < 60 or > 60 ml/min per 1.73 m2, which identifies stage 3 kidney disease (32) (Table 7). Classification of subjects by cysC-eGFR was of comparable significance to HDLC concentrations in explaining variance in plasma PON1 concentrations for both the total cohort and for those subjects with a duration of diabetes <15 years.
###end p 36
###begin p 37
###xml 123 124 123 124 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
Regression analysis with ln PON1 as the dependent variable and cystatin C eGFR as less than or greater than 60 ml/min/1.73m2
###end p 37
###begin title 38
DISCUSSION
###end title 38
###begin p 39
###xml 66 70 66 70 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PON1</italic>
###xml 119 120 119 120 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib9">9</xref>
###xml 120 120 120 120 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib10"/>
###xml 120 120 120 120 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib11"/>
###xml 121 123 121 123 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib12">12</xref>
###xml 641 642 641 642 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 702 703 702 703 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
Although several previous reports have documented associations of PON1 gene polymorphisms with diabetic complications (9-12), less information is available from studies measuring circulating concentrations of PON1, and no previous study of subjects with diabetes has looked specifically at the relationship of PON1 mass and cystatin C. In the present analysis, we demonstrated a significant, independent inverse association of PON1 mass with cystatin C, a novel marker of kidney function, in Aboriginal subjects with type 2 diabetes. It was found that this was explained by lower PON1 mass for subjects with a cysC-eGFR <60 ml/min per 1.73 m2 compared with subjects with cysC-eGFR >60 ml/min per 1.73 m2.
###end p 39
###begin p 40
###xml 87 89 87 89 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib10">10</xref>
###xml 91 93 91 93 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib11">11</xref>
Previous research on PON1 and diabetic kidney disease has focused on microalbuminuria (10, 11). We did not find an association between PON1 mass and urinary albumin:creatinine ratio in our study. The most likely explanation for an absence of association of PON1 mass with microalbuminuria is the relatively short duration of diabetes in this cohort, with a median time of 8 years, compared with 14 years for other studies.
###end p 40
###begin p 41
###xml 130 132 130 132 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib28">28</xref>
###xml 134 136 134 136 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib33">33</xref>
###xml 136 136 136 136 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib34"/>
###xml 137 139 137 139 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib35">35</xref>
###xml 420 422 409 411 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib36">36</xref>
###xml 440 442 429 431 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib37">37</xref>
Serum cystatin C concentrations are an indicator of glomerular filtration rate and strongly correlate with iothalamate clearance (28, 33-35). There are several possible explanations for the association of PON1 mass and of the ratio of PON1/apoAI with GFR as reflected by plasma cystatin C concentrations. PON1 expression has been reported to be reduced by interleukin 1-beta and tumor necrosis factor-alpha (TNF-alpha) (36). Keller et al. (37) reported a significant correlation between cystatin C and TNF-alpha in elderly individuals. Thus, an inflammatory cytokine, such as TNF-alpha, could link reduced renal function and reduced PON1 concentrations.
###end p 41
###begin p 42
###xml 117 119 117 119 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib38">38</xref>
###xml 217 219 217 219 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib39">39</xref>
###xml 357 359 357 359 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib38">38</xref>
###xml 443 445 443 445 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib40">40</xref>
###xml 558 560 558 560 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib41">41</xref>
###xml 668 670 668 670 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib42">42</xref>
###xml 609 614 <span type="species:ncbi:10090">mouse</span>
Serum PON1 is correlated with HDL in normal subjects and is found in both apoAI- and apoAII-containing lipoproteins (38). Association of PON1 with apoAI has been shown to be important for the stability of the enzyme (39), and in vitro studies have suggested that this stability is greater for PON1 associated with LpAI:AII compared with LpAI HDL particles (38). Subjects with diabetes have been reported to have lower LpAI:AII concentrations (40), whereas LpAI has been reported to be reduced in subjects with chronic renal failure with or without diabetes (41). We have recently shown that the PON1 knockout mouse has an inflammatory vascular phenotype on chow diet (42). Clearly there is potential for an interaction between the inflammatory and metabolic changes of diabetes to result in lower serum PON1. The extent to which the lower PON1 and the subsequent reduction in anti-inflammatory function of HDL contribute to vascular and renal changes remains to be determined.
###end p 42
###begin p 43
###xml 76 78 76 78 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib43">43</xref>
###xml 80 82 80 82 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib44">44</xref>
###xml 135 139 135 139 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PON1</italic>
###xml 158 162 158 162 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PON1</italic>
###xml 183 187 183 187 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PON2</italic>
###xml 281 285 281 285 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PON1</italic>
###xml 380 384 380 384 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PON1</italic>
###xml 391 393 391 393 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib44">44</xref>
###xml 453 457 453 457 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PON2</italic>
###xml 531 535 531 535 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PON1</italic>
###xml 624 628 624 628 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PON1</italic>
###xml 633 637 633 637 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PON2</italic>
###xml 719 723 719 723 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PON1</italic>
###xml 946 950 946 950 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PON2</italic>
###xml 1024 1026 1024 1026 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib15">15</xref>
###xml 1064 1073 1064 1073 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PON1/PON2</italic>
###xml 1292 1301 1292 1301 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PON1/PON2</italic>
The genetic polymorphisms of the paraoxonase gene family locus are complex (43, 44). Linkage disequilibrium exists not only within the PON1 gene, but between PON1 and the neighboring PON2 gene, although these relationships vary widely across different geographical ancestries. The PON1 promoter polymorphism at position -162 nucleotides has been suggested to affect expression of PON1 mRNA (44). The linkage disequilibrium of this polymorphism with the PON2 Ala148Gly polymorphism prevents us from ascribing the genetic effects on PON1 concentration to a single polymorphism. However, the lack of an association between the PON1 and PON2 polymorphisms and cystatin C concentration suggests that genetic determinants of PON1 concentration are not affecting renal function, within the limitations of the relatively small sample size studied here. The observed relative risk of 1.25 for the development of microalbuminuria for heterozygotes for the PON2 Ala148Gly polymorphism in the United Kingdom Prospective Diabetes Study (15) is consistent with variation at the PON1/PON2 locus contributing to susceptibility for diabetic nephropathy. However, our data would suggest that the effect of renal function on PON1 concentration is of a significantly greater magnitude than that of the effect of PON1/PON2 genetic variation on renal function.
###end p 43
###begin p 44
###xml 101 103 101 103 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib45">45</xref>
###xml 196 198 196 198 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib45">45</xref>
###xml 503 505 503 505 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib46">46</xref>
###xml 591 592 591 592 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib5">5</xref>
###xml 769 770 769 770 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 883 884 883 884 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 186 194 <span type="species:ncbi:9606">patients</span>
###xml 493 501 <span type="species:ncbi:9606">patients</span>
###xml 957 965 <span type="species:ncbi:9606">patients</span>
###xml 1099 1107 <span type="species:ncbi:9606">patients</span>
It has been demonstrated that PON1 activity is lower in subjects on dialysis compared with controls (45). In contrast, PON1 activity was not different from controls in kidney transplant patients (45). This is consistent with impaired renal function resulting in reduced PON1 and suggests that PON1 is a biomarker of renal impairment. The extent of reduction in PON1 is likely to be important, as it has been reported that lower PON1 mass predicted higher mortality in maintenance hemodialysis patients (46) and lower PON1 activity predicted occurrence of combined cardiovascular end points (5). The mean PON1 mass, adjusted for age, sex, duration of diabetes, and HDLC, was 143 mg/L for the subjects with the PON2 148Ala/Ala genotype and cysC-eGFR <60 ml/min per 1.73 m2 (n = 5) compared with 186 mg/L for the subjects with the PON2 GG148 genotype and cysC-eGFR >60 ml/min per 1.73 m2 (n = 15). This reduction in PON1 mass is comparable to that observed in patients on dialysis (dialysis 129.5 +/- 43.3 vs control 189.5 +/- 44.1, mg/L PON1) (J. Kanampuza et al., unpublished observations). Thus, in patients with diabetic nephropathy, but without renal failure, the presence of the PON2 AA148 genotype is associated with a metabolic profile that is indistinguishable from renal failure requiring dialysis.
###end p 44
###begin p 45
In conclusion, we have found a significant, independent inverse association of PON1 with cystatin C, a novel marker of GFR. Future studies of subjects at risk for vascular disease will be required to determine whether the association of PON1 with inflammatory markers is part of a complex including decreased renal function.
###end p 45
###begin title 46
Abbreviations
###end title 46
###begin p 47
apoAI, apolipoprotein AI
###end p 47
###begin p 48
cysC, cystatin C
###end p 48
###begin p 49
eGFR, estimated glomerular filtration rate
###end p 49
###begin p 50
HDLC, high density lipoprotein cholesterol
###end p 50
###begin p 51
###xml 7 8 7 8 <sub xmlns:xlink="http://www.w3.org/1999/xlink">e</sub>
ln, loge
###end p 51
###begin p 52
PON1, paraoxonase 1
###end p 52
###begin p 53
T1DM, type 1 diabetes mellitus
###end p 53
###begin p 54
T2DM, type 2 diabetes mellitus
###end p 54
###begin p 55
TNF-alpha, tumor necrosis factor-alpha
###end p 55
###begin p 56
The authors are indebted to the leadership and community members of Sandy Lake First Nation for their enthusiastic partnership and participation in this project.
###end p 56
###begin p 57
###xml 67 105 67 105 <grant-sponsor xmlns:xlink="http://www.w3.org/1999/xlink">Canadian Institutes of Health Research</grant-sponsor>
###xml 114 152 114 152 <grant-sponsor xmlns:xlink="http://www.w3.org/1999/xlink">Heart and Stroke Foundation of Ontario</grant-sponsor>
###xml 238 288 238 288 <grant-sponsor xmlns:xlink="http://www.w3.org/1999/xlink">Canadian Diabetes Association Research Scholarship</grant-sponsor>
###xml 777 782 <span type="species:ncbi:9606">Human</span>
This research has been supported through operating grants from the Canadian Institutes of Health Research and the Heart and Stroke Foundation of Ontario (T5592 and T6389). A.J.G.H. holds a Canada Research Chair and is supported through a Canadian Diabetes Association Research Scholarship. S.B.H. holds the Ian McWhinney Chair for Studies in Family Medicine at the University of Western Ontario. B.Z. holds the Sam and Judy Pencer Family Chair in Diabetes Research at Mount Sinai Hospital and the University of Toronto. R.R. holds Canadian Institutes of Health Research New Investigator and Canadian Diabetes Association Clinician Scientist Awards. R.A.H. holds the Jacob J. Wolfe Distinguished Medical Research Chair and Edith Schulich Vinet Canada Research Chair (Tier 1) in Human Genetics.
###end p 57
###begin p 58
The online version of this article (available at ) contains supplementary data in the form of two figures.
###end p 58

